When the world shut down, Roche went all-in and carried on its research programs
It was no easy decision to keep clinical trials going last spring, when the Covid-19 pandemic escalated, but Roche quickly decided that it would keep as much research going as it could, says research executive. This is now paying off.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Even though pharmaceutical companies, overall, have not been hit as hard by the Covid-19 pandemic as most other industries, pharmaceutical and biotech companies have been especially challenged in one particular area, which is that of clinical research.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Roche to embrace new technologies early on
For subscribers
